The overall goal of the Mayo Alzheimer Disease Research Center Clinical Core is to support, through the recruitment and careful diagnosis of patients and controls, the various projects on clinical dementia that are ongoing at the Mayo Clinic Rochester and Jacksonville.
The specific aims of the Clinical Core are to: 1. Recruit and follow subjects on the AD degenerative spectrum with a particular focus on early disease (MCI); 2. Recruit African-Americansubjects on the AD degenerative spectrum with special focus on early disease (MCI); 3. Recruit and follow subjects with non-AD dementia, e.g., frontotemporal dementia, dementia with Lewy bodies, corticobasal degeneration; 4. Obtain DMA on control subjects, MCI and dementia patients (AD, frontotemporal dementia and Lewy Body Dementia) in order to support ADRC related genetic projects including Projects 2 and 3;and 5. Supply subjects for the Neuropathology Core and ADRC related projects that require clinical- pathological correlation. In the past grant cycle, the Clinical Core has been very successful in recruiting and retaining subjects. The Core has also been very productive in several areas including in imaging in mild cognitive impairment, Alzheimer disease and the non-Alzheimer Dementias. The Core was also heavily involved in the genetic advances in frontotemporal lobar degeneration, as some of the pivotal families the mutations in the PGRN gene were initially recruited and evaluated in the Clinical Core. For the current proposal, we intend to continue to recruit normal volunteers including both whites and African Americans. We will also recruit patients with mild cognitive impairment, Alzheimer disease, Lewy body dementia, frontotemporal lobar degeneration and corticobasal degeneration. All of our subjects will be characterized according to the criteria of the Uniform Data Set specified by the NACC.
(Seeinstructions): The Clinical Core is the centerpiece of the Mayo ADRC. The Core recruits, characterizes and follows a large number of normal control subjects as well as patients with mild cognitive impairment and various dementias, who then are the participants in the various research projects supported by the ADRC.
|Kertesz, A; Finger, E; Murrell, J et al. (2015) Progressive supranuclear palsy in a family with TDP-43 pathology. Neurocase 21:178-84|
|Zhang, Bing; Ferman, Tanis J; Boeve, Bradley F et al. (2015) MRS in mild cognitive impairment: early differentiation of dementia with Lewy bodies and Alzheimer's disease. J Neuroimaging 25:269-74|
|Nedelska, Zuzana; Ferman, Tanis J; Boeve, Bradley F et al. (2015) Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiol Aging 36:452-61|
|Steffen, Teresa M; Boeve, Bradley F; Petersen, Cheryl M et al. (2014) Long-term exercise training for an individual with mixed corticobasal degeneration and progressive supranuclear palsy features: 10-year case report follow-up. Phys Ther 94:289-96|
|Shinohara, Mitsuru; Fujioka, Shinsuke; Murray, Melissa E et al. (2014) Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease. Brain 137:1533-49|
|van Blitterswijk, Marka; Mullen, Bianca; Wojtas, Aleksandra et al. (2014) Genetic modifiers in carriers of repeat expansions in the C9ORF72 gene. Mol Neurodegener 9:38|
|Cannon, Ashley; Bieniek, Kevin F; Lin, Wen-Lang et al. (2014) Concurrent variably protease-sensitive prionopathy and amyotrophic lateral sclerosis. Acta Neuropathol 128:313-5|
|Mielke, Michelle M; Weigand, Stephen D; Wiste, Heather J et al. (2014) Independent comparison of CogState computerized testing and a standard cognitive battery with neuroimaging. Alzheimers Dement 10:779-89|
|Graff-Radford, Jonathan; Murray, Melissa E; Lowe, Val J et al. (2014) Dementia with Lewy bodies: basis of cingulate island sign. Neurology 83:801-9|
|Winslow, Ashley R; Moussaud, Simon; Zhu, Liya et al. (2014) Convergence of pathology in dementia with Lewy bodies and Alzheimer's disease: a role for the novel interaction of alpha-synuclein and presenilin 1 in disease. Brain 137:1958-70|
Showing the most recent 10 out of 556 publications